跳至主要内容
临床试验/NCT07260344
NCT07260344招募中不适用

Evaluation of Two Non-Invasive Methods, High-Resolution Microendoscopy and Liquid-Based Cytology, for Detection of Oral Precancer

Anil Chaturvedi1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2025年12月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
400
试验地点
1
主要终点
Prevalence of oral dysplasia

研究概览

简要总结

Cancers of the oral cavity (lip, oral tongue, gingivae, floor of mouth, hard palate, and other mouth tissues including buccal mucosa) are amongst the most common worldwide, with an estimated annual burden of over 300,000 incident cases. Most oral cancers (>75%) are attributable to cigarette smoking, alcohol drinking, and chewing of areca nut/betel quid with or without tobacco, and very few are related to human papillomavirus infection. Oral cancer incidence geographically tracks with the prevalence of these risk factors and is notably high in the Indian subcontinent (due to tobacco chewing and smoking) and southeast Asia (due to betel quid chewing without tobacco and smoking).

The current standard for screening for oral precancer/cancer is visual and tactile examination by an expert for the presence of clinical/visual lesions (leukoplakia, erythroplakia, and oral submucous fibrosis). Such visually identified lesions are further triaged based on clinical impression for a biopsy to determine histopathologic presence/grade of dysplasia. Several observations point to key limitations of oral cancer screening based on clinical impression-based biopsy of visually identified lesions, including the decision to biopsy a lesion, which lesion to biopsy, and where within the lesion to direct a biopsy. Thus, there is a need for tools for improved triage of visual precancers for biopsy and targeting areas for biopsy within a lesion for more effective risk stratification and better provision of care.

Two non-invasive methods hold promise for triage of lesions for biopsy-oral liquid-based cytology and high-resolution microendoscopy (HRME). Oral cytology provides a method to non-invasively sample visible oral lesions and holds promise to enable triage of lesions for biopsy. HRME utilizes optical fiber-based imaging in combination with the fluorescent contrast agent proflavine to image sub-cellular features in vivo in lesions/epithelial tissues, functionally an in situ biopsy.

The investigators propose to conduct a cross-sectional study to evaluate the clinical utility of these two non-invasive methods for detecting oral precancer and early oral cavity cancer- the performance of oral cytology and HRME as an adjunct for triage of visible lesions for biopsy and the performance of HRME as an adjunct to enable better within-lesion targeting of areas for biopsy. If successful, this study would facilitate the development of a non-invasive, 3-step algorithm for oral cancer screening: identification of lesions through visual inspection, triage for biopsy through cytology or HRME, and targeted within-lesion biopsy (if needed) through HRME.

详细描述

The investigators propose to conduct a cross-sectional randomized study to evaluate the performance of oral cytology and HRME (separately) versus clinical impression for triage of lesions for biopsy and the performance of HRME-directed biopsies versus clinician-directed biopsies. Performance will be evaluated based on yield of histopathologic disease- defined as diagnosis of any dysplasia (encompassing mild dysplasia, moderate dysplasia, severe dysplasia, or cancer) and high-grade disease (encompassing moderate dysplasia or above).

Upon identification of visible lesions, study investigators will ask the clinicians to provide a clinical impression regarding whether or not they would biopsy each lesion. Patients with visual oral precancer will then be randomized to one of two arms: 1) a standard-of-care clinical-directed biopsy arm or 2) HRME-directed biopsy arm. The biopsy decision in the clinical-biopsy arm will be guided by clinical impression/ examination under white light and the biopsy decision in the HRME-biopsy arm will be guided by HRME features. However, clinical impression and HRME features will be collected in both arms. Such availability of data will enhance the sample sizes for comparisons of clinical site of biopsy versus HRME site of biopsy.

The study specific aims are:

Aim 1: To evaluate the performance of oral cytology or HRME for triage of visually-identified lesions for biopsy. For cytology evaluation, this aim will combine participants from both arms and thus be non-randomized. For HRME evaluation, this aim will utilize participants from the HRME-directed biopsy arm. The yield of histopathologic disease will be compared between clinicians' response as to whether or not they would biopsy a lesion versus oral cytology or versus HRME.

Aim 2: To evaluate the performance of HRME for within-lesion targeting of regions for biopsy. This aim will be a randomized comparison of diagnostic yields of histopathologic disease between the clinician-directed biopsy arm versus the HRME-directed biopsy arm.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Screening
盲法
None

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Individuals aged 30-80 years
  • Individuals with visible oral precancerous lesions of at 1 cm in greatest diameter

排除标准

  • Individuals who are undergoing current cancer treatment or had a cancer within the last 12 months
  • Individuals who are unwilling or unable to provide informed consent to participate

研究组 & 干预措施

Standard of care arm

Active Comparator

Patients randomized to the standard of care arm will receive biopsy of visible oral precancer based on clinical assessment.

干预措施: Standard of care (Other)

HRME arm

Experimental

Patients randomized to the HRME arm will receive biopsy of visible oral precancer based on high-resolution microendoscopy assessment.

干预措施: High-resolution microendoscopy of visible oral precancerous lesions (Device)

结局指标

主要结局

Prevalence of oral dysplasia

时间窗: At study enrolment

Prevalence of any grade of dysplasia or high-grade dysplasia (moderate dysplasia, severe dysplasia, or cancer)

次要结局

未报告次要终点

研究者

发起方
Anil Chaturvedi
申办方类型
Nih
责任方
Sponsor Investigator
主要研究者

Anil Chaturvedi

Senior Investigator

National Institutes of Health Clinical Center (CC)

研究点 (1)

Loading locations...

相似试验